Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001210 · ClinicalTrials.gov registry record
Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 60
- Enrollment target
NCT00001210: Completed study, sponsored by National Cancer Institute (NCI).
NCT00001210 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001210 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
Subjects are healthy adult volunteers either at high risk for HIV infection or already known to be seropositive, who will donate blood for in vitro tests of T-cell function and in vitro responses to synthetic peptides corresponding to sequences from HIV proteins.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 1986-11 |
| Est. Completion | 2000-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001210
The ClinicalTrials.gov registry entry for NCT00001210 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00001210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001210 about?
NCT00001210 is a clinical study titled "Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines". Subjects are healthy adult volunteers either at high risk for HIV infection or already known to be seropositive, who will donate blood for in vitro tests of T-cell function and in vitro responses to synthetic peptides corresponding to sequences from HIV proteins.
What is the current status of trial NCT00001210?
This trial is currently completed. The enrollment target is 60 participants. The study started on 1986-11. Estimated completion is 2000-09.
Who is sponsoring clinical trial NCT00001210?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.